

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2011

	Current Quarter Ended 31.12.2011 (Unaudited) RM'000	Corresponding Quarter Ended 31.12.2010 (Unaudited) RM'000	Current Year-To-Date Ended 31.12.2011 (Unaudited) RM'000	Corresponding Year-To-Date Ended 31.12.2010 (Audited) RM'000
Revenue	8,470	8,418	31,617	29,492
Operating profit	2,596	2,693	10,778	10,160
Operating expenses	(1,992)	(1,803)	(7,906)	(7,196)
Finance costs	(132)	(118)	(490)	(446)
Profit before taxation	472	772	2,382	2,518
Tax expense	(182)	(66)	(622)	(370)
Profit after taxation	290	706	1,760	2,148
Other comprehensive income, net of tax	(9)	-	(5)	3,187
Total comprehensive income	281	706	1,755	5,335
Profit after taxation attributable to Owners of the Company:	290	706	1,760	2,148
Total comprehensive income attributable to Owners of the Company:	281	706	1,755	5,335
Earnings per share (sen) attributable to Owners of the Company: - Basic	0.19	0.47	1.18	1.44

Note:-

The above condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS AT 31 DECEMBER 2011

	As At Current Year Quarter 31.12.2011 (Unaudited) RM'000	As At Financial Year End 31.12.2010 (Audited) RM'000
ASSETS		
Non - current assets		
Property, plant and equipment	16,279	15,349
Product development expenditure	760	1,009
Goodwill	58	58
Quoted investments	5	16
	<u>17,102</u>	<u>16,432</u>
Current assets		
Inventories	9,557	9,998
Trade receivables	6,394	6,129
Other receivables, deposits and prepayments	732	357
Tax refundable	163	81
Fixed and short term deposits with licensed banks	3,289	4,862
Cash and bank balances with licensed banks and other financial institution	7,094	6,538
	<u>27,229</u>	<u>27,965</u>
TOTAL ASSETS	<u>44,331</u>	<u>44,397</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	14,939	14,939
Share premium	3,520	3,520
Retained profits	16,307	15,219
Fair value reserve	-	5
Revaluation reserve	3,179	3,179
Merger deficit	(8,397)	(8,397)
	<u>29,548</u>	<u>28,465</u>
Non-current liabilities		
Deferred taxation	579	523
Hire purchase payables	229	209
Term loans	5,377	5,003
	<u>6,185</u>	<u>5,735</u>
Current Liabilities		
Trade payables	3,311	4,194
Bill payable	3,101	2,024
Other payables and accruals	1,561	2,406
Amount owing to directors	-	34
Proposed dividend	-	896
Hire purchase payables	126	115
Term loans	499	528
	<u>8,598</u>	<u>10,197</u>
TOTAL LIABILITIES	<u>14,783</u>	<u>15,932</u>
TOTAL EQUITY AND LIABILITIES	<u>44,331</u>	<u>44,397</u>
Net assets per share (RM) attributable to owners of the Company	<u>0.20</u>	<u>0.19</u>

Note:-

The above condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.

The net assets per share attributable to owners of the Company is calculated based on net assets value and the issued paid up share capital of 149,390,500 shares.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2011

			Non-distributable		Distributable		
	Share Capital RM'000	Share Premium RM'000	Fair Value Reserve RM'000	Revaluation Reserve RM'000	Merger Deficit RM'000	Retained Profits RM'000	Total Equity RM'000
<u>12 months ended 31 December 2011</u>							
(Unaudited)							
Balance at 1 January 2011	14,939	3,520	5	3,179	(8,397)	15,219	28,465
Total comprehensive income for the financial year	-	-	(5)	-	-	1,760	1,755
Tax-exempt dividend	-	-	-	-	-	(672)	(672)
Balance at 31 December 2011	14,939	3,520	-	3,179	(8,397)	16,307	29,548
<u>12 months ended 31 December 2010</u>							
(Audited)							
Balance at 1 January 2010 - as previously reported	14,939	3,520	-	-	(8,397)	13,966	24,028
Effects of adopting FRS 139	-	-	(2)	-	-	-	(2)
Balance at 1 January 2010 - as restated	14,939	3,520	(2)	-	(8,397)	13,966	24,026
Total comprehensive income for the financial year	-	-	7	3,180	-	2,148	5,335
Realisation of revaluation reserve	-	-	-	(1)	-	1	-
Interim tax-exempt dividend	-	-	-	-	-	(896)	(896)
Balance at 31 December 2010	14,939	3,520	5	3,179	(8,397)	15,219	28,465

Note:-

The above condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2011

	Current Year To Date Ended 31.12.2011 (Unaudited) RM'000	Corresponding Year To Date Ended 31.12.2010 (Audited) RM'000
Cash flows from/(for) operating activities		
Profit before taxation	2,382	2,518
Adjustments for:-		
Depreciation of property, plant and equipment	628	645
Non-cash items	867	1,077
Operating profit before working capital changes	3,877	4,240
Changes in working capital	(1,234)	(980)
Tax paid	(647)	(46)
Tax refunded	-	200
Interest paid	(459)	(391)
Net cash from operating activities	1,537	3,023
Cash flows from/(for) investing activities		
Interest received	125	133
Payment for product development expenditure	-	-
Purchase of property, plant and equipment	(1,437)	(3,065)
Proceeds from disposal of property, plant and equipment	113	139
Proceeds from disposal of quoted investment	17	-
Net cash for investing activities	(1,182)	(2,793)
Cash flows from/(for) financing activities		
Drawdown of term loans	665	5,558
Repayment of term loans	(325)	(4,228)
Advances from/(Repayment to) directors	(47)	7
Repayment of hire purchase obligations	(97)	(207)
Payment of dividend	(1,568)	-
Net cash from/(for) financing activities	(1,372)	1,130
Net decrease in cash and cash equivalents	(1,017)	1,360
Cash and cash equivalents at beginning of the financial year	11,400	10,040
Cash and cash equivalents at end of the financial year	10,383	11,400
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	3,289	4,862
Cash and bank balances with licensed banks and other financial institution	7,094	6,538
	10,383	11,400

Note:-

The above condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.